Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Acta Haematologica|November 5, 2005
Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cellsNeal Flomenberg, John DiPersio, Gary Calandra
Current Topics in Microbiology and Immunology|April 17, 2010
CXCR4 in clinical hematologyGary Calandra, Gary Bridger, Simon Fricker
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2009
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myelomaDouglas A Stewart, Clayton Smith, Ron MacFarland, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 14, 2010
Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantationNeal Flomenberg, Raymond L Comenzo, Karin Badel, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 15, 2009
A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairmentRonald MacFarland, Marjie L Hard, Robert Scarborough, et al.
Stem Cells and Development|September 6, 2007
Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patientsYair Gazitt, Cesar O Freytes, Cagla Akay, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2008
A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphomaAmanda Cashen, Sandra Lopez, Feng Gao, et al.
Leukemia & Lymphoma|August 7, 2009
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and NilotinibFalk Dillmann, Marlon R Veldwijk, Stephanie Laufs, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 27, 2009
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patientPatrick Stiff, Ivana Micallef, Philip McCarthy, et al.
Annals of Hematology|April 18, 2007
Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myelomaUta Oelschlaegel, Martin Bornhauser, Sabine Boxberger, et al.
Pageof 3